tislelizumab + bevacizumab + platinum + pemetrexed

This is a combination regimen consisting of four agents: - **Tislelizumab** is a humanized IgG4 monoclonal antibody targeting PD-1, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor immunity. - **Bevacizumab** is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and tumor blood supply. - **Platinum** refers to platinum-based chemotherapeutic agents, most commonly carboplatin or cisplatin, which induce DNA crosslinking and apoptosis in rapidly dividing cells. - **Pemetrexed** is an antifolate chemotherapy agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, leading to inhibition of DNA replication and cell death. This combination has been studied primarily for advanced non-squamous non-small cell lung cancer (NSCLC) with driver-gene mutations after tyrosine kinase inhibitor failure. The regimen leverages immunotherapy (tislelizumab), antiangiogenic therapy (bevacizumab), and cytotoxic chemotherapy (platinum plus pemetrexed) for synergistic antitumor effects[1][3].